Evaluation of anti-inflammatory and anti-angiogenesis effects of naloxone in the rat air pouch model of inflammation

Tahereh Eteraf-Oskouei1, Atefeh Zabiholahi2, Moslem Najafi3, Bohlool Habibi-Asl3

1 PhD of Pharmacology, Associate Professor, Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
2 PharmD, Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
3 PhD of Pharmacology, Professor, Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

Type of article: Original

Abstract

Background and objective: There is increasing evidence that the nervous system is in two-way interaction with the immune system. To study the relationship between the opioid and immune systems, the anti-inflammatory effect of naloxone - an opioid receptor antagonist - in the air pouch model as an animal model of rheumatoid arthritis was studied.

Methods: Sterile air (20 and 10 ml) was subcutaneously injected into the back of the animals on days 1 and 3, respectively. On the 6th day, carrageenan was injected into the pouch. Normal saline and different doses of naloxone were injected immediately, as well as 24 and 48 hours after carrageenan in the control and treatment groups, respectively. After 72 hours, granulation tissue was opened, the pouch fluid was collected to determine the volume of exudates, the concentration of Vascular Endothelial Growth Factor (VEGF) and Interleukin 1 beta (IL-1β) and count of leukocyte. Granulation tissue was extruded and weighed. To assay the angiogenesis, the granulation tissue was homogenized and centrifuged, and the supernatant was filtered by a 0.22µ filter. Hemoglobin concentration was determined by the hemoglobin kit.

Results: Naloxone clearly reduced leukocyte accumulation (p<0.01), exudate volume (p<0.001), granulation tissue weight (p<0.01), and amount of angiogenesis in the granulation tissue (p<0.001). In addition, VEGF and IL-1β levels were decreased significantly (p<0.01) and (p<0.001), respectively.

Conclusion: Naloxone can reduce inflammatory and angiogenesis parameters in an air pouch inflammatory model. The anti-inflammatory effect is probably related to inhibition of leukocyte accumulation due to decreased concentration of inflammatory cytokines in exudates.

Keywords: Naloxone, Inflammation, Angiogenesis, Vascular Endothelial Growth Factor, Interleukin-1

Abbreviations / Acronyms:
IL-1β: Interleukin 1 beta; NO: Nitric Oxide; PBS: Phosphate Buffer Solution; RA: Rheumatoid Arthritis; RCF: Relative Centrifugal Force; VEGF: Vascular Endothelial Growth Factor

1. Introduction
The connection between the nervous system and the immune system has attracted researchers’ attention for many years, and several articles have been published in this area (1). The two systems have the same function at the cellular level. The immune system cells, like the nervous system, have two-way communication, and exchange information between each other. Different proteins that were considered to be unique to the nervous system have recently been found in the immune system (2). Immune system cells independently produce neuropeptides and...
neurotransmitters, for example, lymphocytes produce peptide hormones, and neurotransmitters such as acetylcholine, serotonin, and endorphins (3). Research has also indicated that there are receptors for neuropeptides on the surface of immune system cells (4, 5). In other words, the immune system acts through chemical mediators like a sensory organ for the nervous system (6). In recent years, our research has been focused on the axis of this two-way communication and in the case of oxytocin, adrenergic and serotoninergic systems, have yielded interesting results (7-9). Considering the role of opioids and their receptors in the immune system and in chronic inflammatory conditions such as rheumatoid arthritis (10, 11), this study aimed to investigate the role of the opioid system in peripheral inflammation and angiogenesis using naloxone - an opioid receptor antagonist - in the air pouch inflammatory model in rats. The air pouch model is developed by subcutaneous injection of sterile air into the back of the rat. After the air is injected, a cavity is formed that consists of some cells, including primary macrophages and fibroblasts. After six days, this structure is similar to the joint structure, and the inflammation examined in this model is a mimic of joint inflammation (12). Angiogenesis and chronic inflammation in pathological conditions, including rheumatoid arthritis, have interactive effects on each other, and in most cases, angiogenesis is effective in the progression of chronic inflammation, while chronic inflammation also provides conditions for the progression of angiogenesis (13). Considering this, inhibition of angiogenesis is an important therapeutic target in chronic inflammatory diseases like rheumatoid arthritis (RA) (14). In this study, the effects of naloxone on inflammatory and angiogenesis parameters, Vascular Endothelial Growth Factor (VEGF) and Interleukin 1 beta (IL-1β) concentrations in exudate fluid were investigated.

2. Material and Methods

2.1. Chemicals

The following chemicals were obtained: Naloxone (Tolid Darou, Iran), Carrageenan (Sigma, Germany), Ethylenediaminetetraacetic acid (Merck, Germany), hemoglobin kit and Drabkin reagent (ZistChem Diagnostics, Iran), VEGF kit (Hangzhou Eastbiopharm, USA), Ethylene Diamine Tetra Acetic Acid, and IL-1β kit (BosterBio USA). All other chemicals were of the highest grade commercially available.

2.2. Animal

Male Wistar rats (200 -250 g, Pasture Institute, Tehran, Iran) were used in 5 groups of 6 animals. The animals were kept at the animal house of the Faculty of Pharmacy affiliated with Tabriz University of Medical Sciences, Tabriz, Iran and acclimatized to the laboratory environment for at least 1 h before the experiments, and used only once throughout the study. The animals had free access to water and food, and they were kept under standard conditions at 22±3 °C and 12 hours of light and 12 hours of darkness in a light cycle.

2.3. Research ethics

The present study was performed in accordance with the Guide for the Care and Use of Laboratory Animals of Tabriz University of Medical Sciences, Tabriz-Iran (NO. 3836).

2.4. Creation of air pouch model of inflammation by carrageenan in rats

After light anesthesia, the hair on the back of the animals was shaved, the injection site was disinfected by ethanol 70%, and then 20 ml of sterile air was subcutaneously injected into the back of the rats. To minimize tissue damage during injection, a fine needle (25 G) was attached to the syringe. Three days later, again, after anesthetizing the animal, 10 ml of sterile air was injected into the same region. On the sixth day after the first injection, 2 ml of 2% carrageenan was injected into the cavity on the back of the anesthetized animal (Figure 1). To prevent possible infection, the suspension of carrageenan was autoclaved at 121 °C for 15 minutes (12). In the control group, normal saline and in the test groups, naloxone (100, 200, 400 and 800 µg/pouch) was injected into the pouch of each rat at a dose of 1 ml just before carrageenan injection and then for 2 consecutive days. Three days after the last injection, the rats were euthanized and after shaving the entire hair of the animal's back area, the skin surface on the pouch was carefully disinfected by 70% ethanol. After drying the site, the pouch was gently opened with sharp scissors, and the inflammatory exudate was syringed and then its volume was measured. Exudate accumulation following carrageenan injection is due to the secretion of inflammatory mediators such as prostaglandins (15). To prevent clotting, some of the exudates were poured into the test tube containing a small amount of Ethylen Diamine Tetra Acetic Acid (EDTA; Merck) and mixed well. Then the exudate was diluted with phosphate buffer solution (PBS), and the number of white blood cells was counted using a neobar lam (Boec; Germany) under a light microscope (Olympus; Japan). Following the injection of carrageenan and induction of inflammation, granulation tissue formed around the pouch, which was carefully separated from the animal in order to weigh it. For this purpose, after collecting all the exudates inside the pouch, the outer skin was cut, and the pouch was removed from the surrounding tissues and weighed (12).
2.5. Determination of the amount of IL-1β and VEGF in exudates

Three days after induction of inflammation, secreted exudates were collected and transferred to test tubes. Then they were centrifuged (1000 rpm for 10 minutes) with refrigerated centrifuge (Eppendorf Centrifuge 5810R; Germany). The supernatant was stored in the freezer to determine the amount of IL-1β and VEGF using commercial ELISA kits, according to the manufacturer's instructions.

2.6. Angiogenesis investigation in granulation tissue

For angiogenesis, granulation tissue was washed gently in PBS and then cut into small pieces. Droebkin solution prepared from the hemoglobin kit, was added and homogenized for 4 minutes at 15,000 and in a 4°C ice bed by a homogenizer (Heidolph; Germany). Homogeneous tissue was then centrifuged (Eppendorf Centrifuge 5810R; Germany) for 30 minutes at 4°C and RCF 1000. The supernatant was filtered by 0.22 µ filter (Millipore), and the amount of hemoglobin in supernatant was measured as an angiogenesis index using standard hemoglobin kits and spectrophotometer apparatus (Shimadzu UV-1800; Japan) at 540 nm wavelength (9).

2.7. Statistical Analysis

Data are shown as mean ± SEM. The data were analyzed by one-way ANOVA and by LSD post hoc test using the SPSS ver.17 software. Any difference between the groups with the level of P<0.05 was considered significant.

3. Results

3.1. Effect of naloxone on the cellular infiltration, exudation and granulation tissue weight

Three days following administration of different doses of naloxone, inflammatory parameters including leukocytes number, volume of exudate and granulation tissue weight were measured. Analysis of the inhibitory profiles using the investigated doses (100, 200 and 400 µg/pouch) of naloxone indicated that significant inhibition of leukocyte migration occurred [by 55.8% (p<0.01), 55.6% (p<0.01) and 74.7% (p<0.001) for each dose, respectively] (Figure 2A). The results showed that 72 hours after inflammation induction, the amount of exudate in the control group was 7.23±0.3 ml. Only 400 µg with a significant level of p<0.001 could reduce the volume of exudates compared to the control group (by 15.6%; Figure 2B). The granulation tissue formed around the pouch after collecting the exudate was isolated from the animal and then weighed. Naloxone showed a significant difference in terms of weight loss in the granulation tissue (p<0.01). Although naloxone at doses of 100 and 800 µg did not change the weight of the
granulation tissue more than that of the control group (4.6±0.1 g), the doses of 200 and 400 µg decreased its weight by 17.4% and 21.7% (p<0.05) respectively, Figure 2C).

Figure 2. Effect of naloxone on leukocyte accumulation (A), exudate volume (B) and granulation tissue weight (C). Asterisks indicate significant difference when compared to the control. *p<0.05, **p<0.01, ***p<0.001 based on ANOVA; NLX= Naloxone.

3.2. Effect of naloxone on angiogenesis 3 days after induction of inflammation

Three days after injection of carrageenan and induction of inflammation, the rat was euthanized, and the granulation tissue formed around the pouch was isolated. After homogenization and centrifugation of the tissue, the supernatant was filtered by a 0.22 µ filter (Sigma, Germany), and the amount of hemoglobin in the tissue was determined as an angiogenesis index by the hemoglobin kit. The anti-angiogenesis effects of naloxone by doses (100, 200, 400 & 800 µg/pouch) on the hemoglobin contents as an angiogenesis marker were 14%, 58%, 25% and 60%, respectively. Naloxone (200 & 800 µg/pouch) produced higher reduction in hemoglobin levels when compared to the control rats (P<0.001; Figure 3).
Figure 3. Evaluation of the effect of naloxone on angiogenesis of granulation tissue (n=6). Values are mean ± SEM shown by vertical bars. Asterisks indicate significant change from control. ***p<0.001 based on ANOVA; NLX= Naloxone.

3.3. Effect of naloxone on VEGF and IL-1β of exudates 3 days after induction of inflammation
Three days after induction of inflammation, the rat was euthanized, inflammatory exudates were collected, and after centrifugation, the concentration of VEGF and IL-1β in the supernatant-lacking inflammatory exudate cells was measured by the ELISA kit. Figure 4 depicts the dose-dependent variations in VEGF and IL-1β concentrations in response to increasing naloxone concentrations. Intra pouch injection of naloxone (100, 200, 400 and 800 µg/pouch) again decreased VEGF levels by 45.1%, 38.2%, 35.6% and 42.8%, respectively; (Figure 4A). Similarly, significant reduction in IL-1β concentrations was also achieved following administration of naloxone (100, 200 and 800 µg/pouch) by 38.8%, 31.2% and 57.2% respectively; (Figure 4B).

Figure 4. The effect of naloxone on the amount of VEGF (A) and IL-1β (B) in the inflammatory exudates (n=6). Values are the mean ± SEM shown by vertical bars. Asterisks indicate significant change from control. **p<0.01, ***p<0.001 based on ANOVA; NLX= Naloxone.
4. Discussion
In the present work, the anti-inflammatory effects of naloxone as an opioid receptor antagonist were investigated in an air pouch inflammatory model. To elucidate the mechanism of anti-inflammatory and anti-angiogenesis effects of naloxone, the concentrations of two candidate proinflammatory mediators were measured. Based on the study results, intra pouch injection of naloxone significantly reduced leukocyte accumulation. Consistent with our results, Cornwell et al. found that the numbers of circulating immune cells were significantly increased with chronic morphine administration (16). Evidence suggests that IL-1 family cytokines interact with central endogenous opioid transporter systems (17). Also, leukocyte infiltration can be regulated by IL-1 (18, 19). Our data confirmed the inhibitory effect of naloxone on IL-1β protein content. It seems that one of the possible mechanisms of naloxone in reducing leukocyte accumulation is decreasing IL-1β production in inflammatory exudates. In another study, Chin et al. (2016) found that naloxone administration reduced the expression of IL-1β gene (20). IL-1 is an inhibitor of proteoglycan synthesis in cartilage, and joint discomfort in people with RA treated with anakinra - a human recombinant IL-1 receptor antagonist - is clearly improved (21).

In this study, naloxone was able to reduce the amount of exudate released into the pouch. Following the injection of carrageenan, vascular permeability increases with the release of mediators such as histamine, serotonin, prostaglandins, leukotrienes and nitric oxide (NO), resulting in inflammatory exudates. In this regard, the role of NO in carrageenan-induced inflammation is particularly significant (22, 23). Liu et al. (2002) observed that naloxone increased NO metabolism by the enzyme (24) that could be another possible mechanism for the effect of naloxone to reduce inflammatory exudates.

The formation of granulation tissue is one of the characteristics of chronic inflammation. In addition, the accumulation of fibroblasts and macrophages, collagen synthesis and angiogenesis are important properties of granulation tissue (25). In this work, the weight of granulation tissue showed a significant reduction following naloxone administrations. In line with the results of this study, Smith et al. (2007) observed a reduction in the progression of Crohn's disease due to the weight loss of granulation tissue by low dose of naltrexone (26). Evidence suggests that accumulation of chemokines in synovial tissue contributes to pathogenesis of synovitis (27). Our findings showed that naloxone decreased proinflammatory cytokine concentration including IL-1β and VEGF which cause joint injury by inducing recruitment of white blood cells, exudation and angiogenesis at the site of inflammation in rat model of arthritis. The cytokines derived from macrophages, such as TNF-α and IL-1, play a crucial role in the formation of granulation tissue, so that these cytokines are also called granulomatogenic cytokines (28). The inhibitory effects on the concentration of TNF-α and IL-1 (29, 30) can be the proposed mechanisms to reduce the weight of granulation tissue by naloxone.

According to studies, NO produced by macrophages is involved in the formation of granulation tissue (31). Regarding the inhibitory effects of naloxone on NO (24), a low NO concentration may be considered another possible mechanism to reduce granulation weight in this model. Here, we demonstrated that naloxone inhibits angiogenesis in inflammatory granulation tissue, and VEGF and IL1β might play a pivotal role in modulating neovascularization by naloxone. Researchers have identified that VEGF production in granulation tissue depends on NO concentration (32). Considering the inhibitory effect of naloxone on VEGF concentrations in this study, reduction of the weight of granulation tissue following naloxone injection can be justified by this probable mechanism. Angiogenesis is involved in various pathological conditions, including tumor growth, metastasis, and RA, as well as in physiological processes such as organ development, wound healing and reproduction. Angiogenesis is one of the essential processes in the natural physiology of the body, and if the balance between the angiogenesis inducing and inhibiting factors is eliminated, conditions for the occurrence of certain diseases are created (33). VEGF acts as a mitogen for vascular endothelial cells and increases angiogenesis (34). Studies have also demonstrated that VEGF increases vascular permeability (35). Naloxone reduced the concentration of VEGF protein in this study. Perhaps, the possible reason for angiogenesis reduction by naloxone is reduction of VEGF concentration in inflammatory exudates.

VEGF is not only a main angiogenic factor but also a pro-inflammatory mediator in the inflammatory process. According to the results obtained by Croll et al. (2004), VEGF increases the leukocyte turnover by increasing ICAM-1 (36). In addition, some inflammatory mediators such as NO, TNFα, IL-1 and IL-6 regulate VEGF function. (37). Data reported by Lunger et al. (2016) showed an inhibitory effect of naloxone and methyl naltrexone on the VEGF and angiogenesis of female genital tract cells under in vitro fertilization (38). Consistent with our findings, Singleton et al. (2006) also found that methyl naltrexone prevented the proliferation and migration of endothelial
cells by reducing expression of the gene and transcription of VEGF receptors (39). The active oxygen species produced by active macrophages and neutrophils are angiogenesis-stimulating factors. These oxidative factors enhance the angiogenesis by stimulating production of VEGF (40). Opioid receptors play a role in the activity of macrophages by regulating the production of hydrogen peroxide and protecting against damage from free radicals (41). The anti-inflammatory and anti-angiogenesis effects of naloxone in the present study are possibly associated with its protective effect against free radicals. Inflammation is increasingly recognized as an important mediator of angiogenesis, and it has been reported that uncontrolled angiogenic response is implicated in chronic inflammation. Angiogenesis in RA results in the accumulation of leukocytes and inflammation in the synovium. In addition, synovial inflammation itself enhances endothelial proliferation and angiogenesis (14). On the other hand, chronic inflammation and angiogenesis play an important role in tumor progression and malignancy (42). So that, antiangiogenic drugs can control angiogenesis-related diseases such as cancer (43).

In the present study, it was observed that the pattern of reduction of inflammatory parameters and angiogenesis of naloxone was in the form of a bell-shape, which the highest effect was in the middle dose and higher and lower doses exhibited different anti-inflammatory effects. The same dose-response curve for protective and analgesic effects of opioid antagonists like naloxone has also been reported. Such a dosing curve may be due to the diversity of opioid receptors and their different densities in the immune system (44).

5. Conclusions
The findings of the present study revealed that naloxone exhibited anti-inflammatory and anti-angiogenesis effects in the air pouch model of inflammation in male rats. The observed effects are probably related to an inhibitory effect on the VEGF and IL-1β concentration by naloxone. Our results may suggest that pharmacological effects of naloxone could have promising benefits in the treatment of many immune-related diseases, such as RA and cancer. Further studies are recommended to elucidate the precise mechanism of action of naloxone in inflammatory conditions. In addition, our findings should be confirmed by histological examination.

Acknowledgments:
The content of this paper was extracted from a thesis submitted for fulfillment of a Pharm.D degree (No.3836) in the Faculty of Pharmacy, Tabriz University of Medical Sciences. The authors would like to thank the Drug Applied Research Center, Tabriz University of Medical Sciences for their technical support.

Conflict of Interest:
There is no conflict of interest to be declared.

Authors' contributions:
All authors contributed to this project and article equally. All authors read and approved the final manuscript.

References:
19) Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 7 ed: Elsevier Health Sciences; 2012.


